[go: up one dir, main page]

ATE115405T1 - Aloe-zusammensetzungen und deren verwendungen. - Google Patents

Aloe-zusammensetzungen und deren verwendungen.

Info

Publication number
ATE115405T1
ATE115405T1 AT89910539T AT89910539T ATE115405T1 AT E115405 T1 ATE115405 T1 AT E115405T1 AT 89910539 T AT89910539 T AT 89910539T AT 89910539 T AT89910539 T AT 89910539T AT E115405 T1 ATE115405 T1 AT E115405T1
Authority
AT
Austria
Prior art keywords
acemannan
defective virus
master seed
aloe compositions
production
Prior art date
Application number
AT89910539T
Other languages
English (en)
Inventor
Bill H Mcanalley
Original Assignee
Carrington Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carrington Lab Inc filed Critical Carrington Lab Inc
Application granted granted Critical
Publication of ATE115405T1 publication Critical patent/ATE115405T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0087—Glucomannans or galactomannans; Tara or tara gum, i.e. D-mannose and D-galactose units, e.g. from Cesalpinia spinosa; Tamarind gum, i.e. D-galactose, D-glucose and D-xylose units, e.g. from Tamarindus indica; Gum Arabic, i.e. L-arabinose, L-rhamnose, D-galactose and D-glucuronic acid units, e.g. from Acacia Senegal or Acacia Seyal; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Materials Engineering (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT89910539T 1988-08-05 1989-08-03 Aloe-zusammensetzungen und deren verwendungen. ATE115405T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/229,164 US5106616A (en) 1988-01-14 1988-08-05 Administration of acemannan

Publications (1)

Publication Number Publication Date
ATE115405T1 true ATE115405T1 (de) 1994-12-15

Family

ID=22860075

Family Applications (2)

Application Number Title Priority Date Filing Date
AT89910539T ATE115405T1 (de) 1988-08-05 1989-08-03 Aloe-zusammensetzungen und deren verwendungen.
AT94105182T ATE192653T1 (de) 1988-08-05 1989-08-03 Anwendungen von acemannan

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT94105182T ATE192653T1 (de) 1988-08-05 1989-08-03 Anwendungen von acemannan

Country Status (8)

Country Link
US (1) US5106616A (de)
EP (4) EP0965345A3 (de)
JP (1) JP2888249B2 (de)
AT (2) ATE115405T1 (de)
AU (1) AU637985B2 (de)
CA (1) CA1336581C (de)
DE (2) DE68920019T2 (de)
WO (1) WO1990001253A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106616A (en) * 1988-01-14 1992-04-21 Carrington Laboratories, Inc. Administration of acemannan
US5308838A (en) * 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
US5468737A (en) * 1982-05-07 1995-11-21 Carrington Laboratories, Inc. Wound healing accelerated by systemic administration of polysaccharide from aloe
US5814611A (en) * 1988-12-14 1998-09-29 Cytoven J.V. Pharmaceutical for the therapy of immune deficiency conditions
US6136788A (en) * 1987-12-30 2000-10-24 Cytran, Inc. Pharmaceutical preparation for the therapy of immune deficiency conditions
US5658957A (en) * 1991-03-01 1997-08-19 Warner Lambert Company Immunostimulating wound healing compositions and method for preparing and using same
WO1993008810A1 (en) * 1991-11-05 1993-05-13 Carrington Laboratories, Inc. Uses of aloe products, e.g. acemannan, in the treatment of diseases requiring intervention of the immune system for cure
IL104382A0 (en) * 1992-01-17 1993-05-13 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant
US5409703A (en) * 1993-06-24 1995-04-25 Carrington Laboratories, Inc. Dried hydrogel from hydrophilic-hygroscopic polymer
US5902796A (en) * 1995-09-22 1999-05-11 Carrington Laboratories, Inc. Bioactive factors of aloe vera plants
US5858378A (en) * 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US6929807B1 (en) * 1996-08-09 2005-08-16 Mannatech, Inc. Compositions of plant carbohydrates as dietary supplements
WO1998006418A1 (en) * 1996-08-09 1998-02-19 Mannatech, Inc. Compositions of plant carbohydrates as dietary supplements
US6303584B1 (en) 1996-11-20 2001-10-16 The University Of Montana Water soluble lipidated arabinogalactan
CU22629A1 (es) * 1997-03-06 2000-12-22 Ct Ingenieria Genetica Biotech Formulaciones inmunopotenciadoras para uso vacunal
US6133440A (en) * 1997-10-10 2000-10-17 Univera Pharmaceuticals, Inc. Process for the preparation of immunomodulatory polysaccharides from aloe
US6136794A (en) * 1998-02-02 2000-10-24 Merck & Co., Inc. Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
CU22740A1 (es) * 1998-09-07 2002-02-28 Ct Ingenieria Genetica Biotech Formulación de ácidos nucleicos y acemanano
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US20030175370A1 (en) * 2002-03-07 2003-09-18 Carrington Laboratories, Inc. Dispersed solid-containing complex carbohydrate
US6884783B2 (en) * 2002-05-03 2005-04-26 Unigen Pharmaceuticals, Inc. 7-Hydroxy chromones as potent antioxidants
US7060304B2 (en) * 2003-04-16 2006-06-13 Access Business Group International Llc Skin whitening compositions containing black cohosh extract
WO2005030232A2 (en) * 2003-07-14 2005-04-07 Shambabu Ayare Herbal compositions for effective treatment of aids, preparation thereof and method for treatment of aids patients
AU2005222069B2 (en) 2004-03-05 2010-09-09 Gen-Probe Incorporated Reagents, methods and kits for use in deactivating nucleic acids
WO2005095463A1 (en) 2004-03-26 2005-10-13 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
EP1736773B1 (de) * 2004-04-16 2014-07-02 Ajinomoto Co., Inc. Testen der potency einer peripheren mononukleären blutzelle zur bindung an polysaccharid
KR100720973B1 (ko) * 2005-03-18 2007-05-22 주식회사 유니젠 천연물 유래 아이소오리엔틴을 포함하는 히스타민 억제용약학 조성물
WO2007024589A2 (en) * 2005-08-24 2007-03-01 The Trustees Of Columbia University In The City Of New York Phagocyte enhancement therapy for atherosclerosis
US8999293B2 (en) 2005-10-13 2015-04-07 University Of Mississippi Animal model of anxiety and depression
WO2007044936A2 (en) * 2005-10-13 2007-04-19 The University Of Mississippi Animal model of anxiety and depression
US20070275150A1 (en) * 2006-05-26 2007-11-29 Ciell Michael P Nutritional composition and method of making the same
KR101388061B1 (ko) * 2006-05-31 2014-04-22 토야마 케미칼 컴퍼니 리미티드 멧돼지과 동물 또는 양(羊)용 항 구제역 바이러스제 및 멧돼지과 동물 또는 양의 구제역의 예방 또는 치료방법
TWI454261B (zh) 2007-01-09 2014-10-01 Unigen Inc 作為治療劑之色酮類
MX2009012210A (es) * 2007-05-11 2010-01-26 Aloebiotics Res Labs Inc Preparacion de aloe para el mejoramiento de la piel.
US7833829B2 (en) * 2008-10-28 2010-11-16 Honeywell International Inc. MEMS devices and methods of assembling micro electromechanical systems (MEMS)
US9511125B2 (en) * 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US9439958B2 (en) * 2009-12-23 2016-09-13 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
US8604187B2 (en) 2010-01-14 2013-12-10 North Texas Medical Associates Compositions and methods of aloe polysaccharides
WO2011146635A1 (en) * 2010-05-21 2011-11-24 North Texas Medical Associates Malignant neoplasm treatment protocol
AU2011282200B2 (en) * 2010-07-23 2015-03-19 Bespoke Bioscience, Llc Anti-viral properties of Aloe vera and Acquired Immune Deficiency Syndrome (AIDS) treatment
BR112013017501B1 (pt) * 2011-01-06 2020-10-27 Bespoke Bioscience, Llc. Método para preparação de um pó fino de um extrato de polimanana, uso do pó fino doextrato de polimanana, formulação injetável de um extrato de polimanana e uso de formulação injetável
US9327029B2 (en) 2011-05-05 2016-05-03 Celacare Technologies, Llc Antimicrobial silver hydrogel composition for the treatment of burns and wounds
JP6129947B2 (ja) * 2015-12-28 2017-05-17 ビスポーク バイオサイエンス，エルエルシー アロエ多糖体の組成物及び方法
WO2019191119A1 (en) 2018-03-28 2019-10-03 Herbalife International Of America, Inc. Acetylation of polysaccharides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892853A (en) * 1967-05-22 1975-07-01 Aloe 99 & 0 Inc Stabilized aloe vera gel and preparation of same
US3470109A (en) * 1968-01-31 1969-09-30 Aloe Creme Lab Inc Method of making reconstitutable aloe gel in crystalline form
US4178372A (en) * 1978-03-06 1979-12-11 Coats Billy C Hypoallergenic stabilized aloe vera gel
US5106616A (en) * 1988-01-14 1992-04-21 Carrington Laboratories, Inc. Administration of acemannan
US4851224A (en) * 1986-06-05 1989-07-25 Carrington Laboratories, Inc. Process for preparation of aloe products
US4555987A (en) * 1983-07-22 1985-12-03 Tumlinson Larry N Method and apparatus for extraction of aloe vera gel
DE3447572A1 (de) * 1984-12-22 1986-07-03 Wolfgang Wirth Mittel zur regenerierung und staerkung tierischer und menschlicher organismen koerpereigener abwehrkraefte und der haut sowie zu deren schutz aus aloe-wirkstoffen
JPS61233627A (ja) * 1985-04-10 1986-10-17 Agency Of Ind Science & Technol 肥満細胞脱顆粒抑制剤
JPS63501221A (ja) * 1985-06-28 1988-05-12 カ−リントン　ラボラトリ−ズ　インコ−ポレ−テツド アロエ製品の製造方法、該方法によって得られた製品およびその組成物
DE3665262D1 (en) * 1985-06-28 1989-10-05 Carrington Lab Inc Processes for preparation of aloe products, products produced thereby and compositions thereof
IL104382A0 (en) * 1992-01-17 1993-05-13 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant

Also Published As

Publication number Publication date
DE68920019D1 (de) 1995-01-26
EP0619117B1 (de) 2000-05-10
EP0619117A2 (de) 1994-10-12
ATE192653T1 (de) 2000-05-15
EP0965345A3 (de) 2000-09-06
EP0857485A3 (de) 1999-03-24
DE68929208D1 (de) 2000-06-15
EP0857485A2 (de) 1998-08-12
EP0382840A4 (en) 1991-04-17
DE68920019T2 (de) 1995-04-20
US5106616A (en) 1992-04-21
EP0382840A1 (de) 1990-08-22
AU4319489A (en) 1990-03-05
JP2888249B2 (ja) 1999-05-10
JPH03501624A (ja) 1991-04-11
CA1336581C (en) 1995-08-08
WO1990001253A1 (en) 1990-02-22
EP0965345A2 (de) 1999-12-22
DE68929208T2 (de) 2000-09-07
EP0382840B1 (de) 1994-12-14
EP0619117A3 (de) 1994-12-21
AU637985B2 (en) 1993-06-17

Similar Documents

Publication Publication Date Title
ATE115405T1 (de) Aloe-zusammensetzungen und deren verwendungen.
MX21218A (es) Procedimiento para preparar una forma de dosificacion farmaceutica para su administracion oral como solido y producto resultante
PT93884A (pt) Processo de preparacao de uma composicao farmaceutica a base de acido 5-amino-salicilico, sob a forma de uma espuma
ATE202778T1 (de) Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
DE3689976D1 (de) Therapeutische Nucleoside und deren Herstellung.
ES538807A0 (es) Un procedimiento para la produccion de un complejo covalentemente unido de inhibidor de alfa-1-proteinasas con un polimero soluble en agua.
DE3485075D1 (de) Pharmazeutische zubereitung zur heilung der erkrankungen der zahnwurzelhaut und verfahren zu deren herstellung.
DE3688038D1 (de) Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.
PT98371A (pt) Processo para a preparacao de derivados 6-alcoxi de arabinofuranosil-guanina e de composicoes farmaceuticas que os contem
ES2106784T3 (es) Factor de transferencia y metodos de uso.
AR004229A1 (es) Derivados indolalquilo de benzodioxanmetilamina y su uso para preparar medicamentos
DE59008170D1 (de) Verfahren zur Herstellung mikronisierter bioabbaubarer Partikel.
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
ATE99945T1 (de) Verwendung von 5'-deoxy-5'-methylthioadenosin s- adenosylmethionin und dessen salzen zur herstellung von seborrhea vermindernden arzneimitteln.
ES2107494T3 (es) Finos de hidrogel absorbente en estructuras absorbentes.
ES536055A0 (es) Un procedimiento para la produccion de un complejo covalentemente enlazado de heparina-antitrombina-iii
ATA379182A (de) Verfahren zur herstellung von presslingen mit retardierter wirkstofffreisetzung
ATE33253T1 (de) Verfahren zur herstellung von reinen dermatansulfat- und herapansulfatglykosaminoglukanen und ihre pharmazeutische verwendung.
ATE209927T1 (de) Pflanzliches produkt zur steuerung der immunantwort in säugern und verfahren zur herstellung des produkts
DE69103624D1 (de) Ipriflavone enthaltende pharmazeutische zubereitungen, verfahren zur herstellung und therapeutische verwendung.
ATE136465T1 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
ES2103413T3 (es) Derivados del androstano sustituidos por un grupo amonio cuaternario en la posicion 16, composiciones farmaceuticas que los contienen y procedimientos para prepararlos.
IT1258315B (it) Derivati del flavone
FR2589063B1 (fr) Procede de culture de babesia canis, application a la preparation d'antigenes et de vaccins, et antigenes et vaccins contre la piroplasmose
FI871479A0 (fi) Menetelmä lääkeaineina käyttökelpoisten perhydrotiatsepiini- ja perhydroatsepiinijohdannaisten valmistamiseksi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee